Analysts at RBC Capital Markets reiterated their Sector Perform rating on shares of Valeant Pharmaceuticals International Inc.
Advertisement
In case of Revenue Estimates, 11 analysts have provided their consensus Average Revenue Estimates for Valeant Pharmaceuticals International, Inc.as 2.51 Billion.
Morgan Stanley has reiterated the shares of Valeant as Overweight and price target of $42.00 on the pharmaceutical company’s stock. The company has grown 3.3% in past 3 months and in the last five trades has moved up 2.29%. Revenues hit $2.42B in the June 2016 quarter, which was below the consensus $2.46B projection. VRX EPS growth this year and EPS growth next year is -133.00%, 17.94% respectively.
Some buy side analysts are also providing their Analysis on Valeant Pharmaceuticals International, Inc., where 3 analysts have rated the stock as Strong buy, 2 analysts have given a Buy signal, 11 said it’s a HOLD, 3 reported it as Underperform and 1 analysts rated the stock as Sell.
According to Reuters, Valeant had been nudging customers towards its own branded versions of drugs rather than lower-cost generics, specifically through pharmacies linked with its in-house mail-order pharmacy, Philidor Rx.
To analyze a stock, one should look for Upgrades and Downgrades of a stock. The stock is now trading at Distance from 20-Day Simple Moving Average of 3.36% while its Distance from 50-Day Simple Moving Average is 7.47 Percent. The shares closed down -0.57 points or -2.92% at $18.93 with 1.69 million shares getting traded. The stock now shows the Market Capitalization of 10.71 Billion. It has twelve month low of $18.55 and twelve month high of $245.82. The stock is now trading at Distance from 20-Day Simple Moving Average of 17.79% while its Distance from 50-Day Simple Moving Average is 29.45 Percent. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.96. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 3.92. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. Company gross margin stands at 57.70% whereas its return on investment (ROI) is 5.70%. While it’s Return on Investment (ROI) value is 3.7%.
Advertisement
During the most recent trading day, the stock’s price shifted up +63.07% from its 52-week low and -87.69% lower from its 52-week high. Year to Date performance value (YTD perf) value is -70.24%. Boothbay Fund Management LLC now owns 7,632 shares of the specialty pharmaceutical company’s stock valued at $201,000 after buying an additional 5,599 shares during the last quarter.
